Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | AGXT | P21549 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7633032 | 0.90 | TDP1 (0.66) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL95651 | 0.88 | TDP1 (0.63) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL16902851 | 0.87 | TDP1 (0.87) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL16893744 | 0.86 | TDP1 (0.61) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL1534971 | 0.86 | TDP1 (0.61) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL16893725 | 0.86 | TDP1 (0.61) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL8778566 | 0.86 | TDP1 (0.61) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL1534924 | 0.86 | TDP1 (0.61) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL29429997 | 0.85 | TDP1 (0.76) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL8565990 | 0.85 | TDP1 (0.76) | TDP1KDM4EMAPK1AGXTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952450-B2 | Compound for encapsulation film and composition thereof, and film, organic light-emitting device and encapsulation method | JILIN OLED OPTICAL AND ELECTRONIC MATERIALS CO., LTD. (CN) | 2024-04-09 | — | — | US | claimed |
| CN-115521230-A | Silicon-containing monomer, photocuring composition, packaging film and organic electroluminescent device comprising packaging film | 吉林奥来德光电材料股份有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-115427049-A | Inhibitors of malaria and plasmodium falciparum hexose transporters and uses thereof | 清华大学 | 2022-12-02 | — | — | CN | claimed |
| CN-114957314-A | Compound for film packaging, composition, packaging film and film packaging structure | 吉林奥来德光电材料股份有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220259352-A1 | Compound for encapsulation film and composition thereof, and film, organic light-emitting device and encapsulation method | JILIN OLED OPTICAL AND ELECTRONIC MATERIALS CO., LTD. (CN) | 2022-08-18 | — | — | US | claimed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | claimed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | claimed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | claimed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2000079312-A1 | HIGH REFRACTIVE INDEX COMPOSITIONS FOR OPHTHALMIC IMPLANTS | BAUSCH & LOMB SURGICAL, INC. (US) | 2000-12-28 | — | — | WO | claimed |
| CN-1224426-A | 3-descladinose-2, 3-anhydroerythromycin derivatives | ABBOTT LAB (US) | 1999-07-28 | — | — | CN | claimed |
| EP-0922050-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-06-16 | — | — | EP | claimed |
| US-5750510-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | claimed |
| WO-1997042205-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | TDP1 1385/4885KDM4E 1122/4885MAPK1 2470/4885 |
| US-20220259352-A1 | Compound for encapsulation film and composition thereof, and film, organic light-emitting device and encapsulation method | AOX1, LOXL1, SEM1 | TDP1 2633/4885KDM4E 1440/4885MAPK1 3159/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | TDP1 1377/4885KDM4E 927/4885MAPK1 2169/4885 |
| US-11952450-B2 | Compound for encapsulation film and composition thereof, and film, organic light-emitting device and encapsulation method | TTPA, LOX, AOX1 | TDP1 3350/4885KDM4E 1222/4885MAPK1 4563/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | TDP1 1385/4885KDM4E 1122/4885MAPK1 2470/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | TDP1 1377/4885KDM4E 927/4885MAPK1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.